Month: September 2021

Highlights Piflufolastat F 18’s Potential to Change Initial Risk Assessment and Intended Patient Management in High-Risk Prostate Cancer Identified Regional Lymph Node and/or Distant Metastases in 26.9% of Patients Prior to Definitive Therapy NORTH BILLERICA, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), an established leader and fully integrated provider committed to innovative imaging diagnostics, targeted therapeutics and artificial intelligence solutions to find, fight and follow serious medical conditions, announced that data from the OSPREY pivotal trial on the utility of piflufolastat F 18 (previously referred to as 18F-DCFPyL or PyL) during initial assessment on men with high risk prostate cancer were presented at the 2021 American Urological Association (AUA) Virtual Annual...

AUSTIN, Texas, Sept. 10, 2021 (GLOBE NEWSWIRE) — Ideal Power Inc. (Nasdaq: IPWR), pioneering the development and commercialization of highly efficient and broadly patented B-TRAN™ bi-directional power switches, today announced that Dan Brdar, President and Chief Executive Officer, and Tim Burns, Chief Financial Officer, will present at the 23rd Annual H.C. Wainwright Global Investment Conference, taking place virtually September 13-15, 2021. Management will also host one-on-one meetings with investors throughout the event. The virtual presentation will be available starting at 7:00 a.m. Eastern Time on September 13, 2021. Registration for the event is accessible via www.hcwevents.com/annualconference. H.C. Wainwright 23rd Annual Global Investment Conference Presentation Date/Time: Virtual presentation will be available starting...

Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract BOCA RATON, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) — AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, therapies for gastrointestinal (GI) diseases, today announced the activation of seven (7) new clinical trial sites in India for the ongoing RESERVOIR trial evaluating FW-1022. FW-1022 is a proprietary oral tablet formulation of micronized niclosamide developed for the treatment of COVID-19-related GI infections. The seven new clinical trial sites in India, together with the existing eleven sites in the U.S. and the five trial sites recently added in the Ukraine, brings the total number of RESERVOIR trial...

HENDERSON, NV, Sept. 10, 2021 (GLOBE NEWSWIRE) — via NewMediaWire — Grove Inc. (the “Company” or “Grove”) (NASDAQ: GRVI), Nevada company engaging in the research, manufacturing, distribution, and marketing of CBD and hemp wellness-based products, today announced that Allan Marshall, Grove’s Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually on September 13-15, 2021. The prerecorded presentation will become available on Monday, September 13, 2021 at 7:00am ET. Management will also be available to participate in one-on-one meetings. Investors may register for the conference at this link, and may also view the presentation by visiting the Events and Presentations section of Grove’s website: https://groveinc.io/investor-relations/. The webcast will be archived...

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) — Brooge Energy Ltd. (“Brooge Energy” or the “Company”) (NASDAQ: BROG), a midstream oil storage and service provider strategically located outside the Strait of Hormuz, in the Port of Fujairah in the United Arab Emirates (the “UAE”), today announced that it will release its financial results for the six months ended June 30, 2021 on Monday, September 13, 2021. The Company will host a conference call to discuss these results on Wednesday, September 15, 2021. Following management’s prepared remarks there will be a question-and-answer session to address any queries investors have regarding the Company’s reported results. Conference Call Information:Date: Wednesday, September 15, 2021Time: 8:00 a.m. ET/4:00 p.m. UAEDial-in Numbers: U.S.: 1-877-425-9470  International: 1-201-389-0878  UAE:...

WOBURN, Mass., Sept. 10, 2021 (GLOBE NEWSWIRE) — Bridgeline Digital, Inc. (NASDAQ: BLIN), a cloud-based marketing technology software provider, announced today that the company would present at the Taglich Brothers 17th Annual Investment Conference at the TWA Hotel at JFK in New York on September 13th at 3:15 pm ET. “The Taglich Brothers Investment Conference is an excellent venue for Bridgeline to meet investors and share its recent success in growing sales and achieving profitability,” said Mr. Kahn. “With COVID-19, many investor conferences canceled, and we’re happy to see the Taglich team put in the effort to make this important event happen.” Bridgeline recently announced its Financial Results for the Third Quarter of Fiscal 2021 with 31% revenue growth with the guidance of 20% growth for its...

Entered definitive merger agreement with Biosight Ltd. to advance pipeline of clinical-stage oncology programs for solid tumors and hematological malignancies Initiated Phase 1 clinical trial of ADXS-504 for the treatment of early prostate cancer ADXS-503 Phase 1/2 data presented at ASCO demonstrate disease control rate of 44% with durable clinical benefit observed beyond one year in patients with disease progression on KEYTRUDA® MONMOUTH JUNCTION, N.J., Sept. 10, 2021 (GLOBE NEWSWIRE) — Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products today announces its financial results for the third quarter ended July 31, 2021 and provides a business update. Third Quarter Ended July 31, 2021 Financial Results and Recent Key Accomplishments:Entered...

JUPITER, Fla., Sept. 10, 2021 (GLOBE NEWSWIRE) — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and deploying its proprietary C1-cell protein production platform to accelerate development, lower production costs and improve the performance of biologic vaccines and therapeutics at flexible commercial scales, today announced that the Company’s management will be attending and presenting at the following upcoming virtual investor event: Event DetailsPresenter: Mark Emalfarb, CEO Date: Monday, September 13, 2021Time: 7:00 AM Eastern Time – Presentation will also be available on demand during the conference September 13 – 15, 2021Event Link: https://hcwevents.com/annualconference/ Dyadic...

LAS VEGAS, Sept. 10, 2021 (GLOBE NEWSWIRE) — via InvestorWire — Golden Triangle Ventures, Inc. (OTC PINK: GTVH) is pleased to announce its Entertainment Division, Lavish Entertainment, Inc., has released its debut experimental bass music album under the Company’s recently formed Record Label, Syndicate Bass Records. The Company has the revolutionary vision to highlight music and visuals on one label by launching animations in concert with each song and distributing this unique content on global streaming video platforms such as YouTube, Vimeo, Twitch and many more. This debut record release will also be available on all major audio streaming platforms such as SoundCloud, Spotify, Apple Music and more. Formed by individuals who believe strongly in the impact of the bass music scene around the world, Syndicate Bass Records...

NEW YORK and LONDON, Sept. 10, 2021 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Miles Nunn, Ph.D., Chief Scientific Officer of Akari Therapeutics, and Sanjeev Khindri, M.D., Medical Director of Akari Therapeutics, will present a poster outlining the design of the Company’s Phase III planned pivotal study of nomacopan in patients with moderate to severe bullous pemphigoid (BP) at the 2021 International Pemphigus & Pemphigoid Foundation (IPPF) Scientific Symposium. The IPPF’s main focus is to improve the quality of life for all those affected by pemphigus and pemphigoid through early diagnosis...